We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Eficacia y seguridad del haloperidol intranasal en una Unidad de Agudos: estudio piloto en pacientes esquizofrénicos con leve-moderada agitación.
- Authors
Ambròs, Rosó Duñó; Oliva Morera, Joan Carles; Iglesias-Lepine, María Luisa; Palao Vidal, Diego; Monreal Ortiz, José Antonio; Labad Arias, Javier
- Abstract
Aim. To study the efficacy and safety of intranasal administration of 5mg haloperidol on mild-moderate agitated patients with schizophrenia or schizoaffective disorder in an acute psychiatry unit setting. Method. Design: Pilot study of clinical trial, phase IV, open-label, observer-blind, single-center, randomized a haloperidol-controlled trial comparing intranasal with intramuscular administration. Subjects: 16 patients; 7 intranasal administration, and 9 intramuscular administration. Efficacy measurement: Positive and Negative Syndrome Scale-Excited Component (PANSS-EC); Clinical Global Impressions-Improvement Scale (CGI). Safety measurement: Changes in the ECG registered 5 minutes pre-treatment and 5 minutes post-treatment. Results. Intranasal administration showed more quick action compared with intramuscular on the PANSS-EC (p=0.042) and CGI (p=0.041) 10 minutes after administration, with similar efficacy up to 20, 30, and 60 minutes. There were no significant differences between QTc baseline and post-treatment. Conclusion. Intranasal haloperidol was a rapid, effective, and well-tolerated alternative for reducing acute mild-moderate agitation.
- Subjects
SELF-efficacy; SCHIZOPHRENIA; SCHIZOAFFECTIVE disorders; PSYCHOMOTOR disorders; EMERGENCY medical services; AGITATION (Psychology); PSYCHOTHERAPY patients; HALOPERIDOL
- Publication
Actas Espanolas de Psiquiatria, 2021, Vol 49, Issue 5, p205
- ISSN
1139-9287
- Publication type
Article